Investors

Company Information

RNA Disease Diagnostics (RNADD) was formed to create a best-in-class rapid and accurate molecular diagnostic technology platform that will contribute to the prevention of infectious disease transmission and to better the health of the citizens of the world. The Company plans to leverage its proprietary Antisense RNA molecular diagnostic platform across multiple diseases and to create highly accurate, quick, affordable, and minimally invasive disease diagnostic testing kits. Working with the University of Maryland, Baltimore (UMB) and the University of Maryland, Baltimore County (UMBC) RNADD has secured an exclusive global license to a cutting-edge molecular sensor technology.

RNADD’s initial focus is to deploy COVID-19 Antisense molecular diagnostic Point Of Care (POC) and Home Use Test (HUT) rapid diagnostic testing kits. The Company operates out of New York, Baltimore, and Toronto, Canada.

Download our Investor Presentation

Accomplished Healthcare Industry Veteran, Richard G. Ganz, Joins RNA Disease Diagnostics’ Board of Directors

July 8, 2021

RNA Disease Diagnostics, Inc. (RNADD) announced today the appointment of Richard G. Ganz to its Board of Directors. Mr. Ganz brings more than forty years of executive experience to RNADD, having worked with businesses ranging from venture-backed startups to major international healthcare companies.

Read More

RNA Disease Diagnostics Announces University of Maryland School of Medicine Laboratory Secures FDA Registration and Approval as Development Site for Antisense COVID-19 Test

June 3, 2021

RNA Disease Diagnostics, Inc. (RNADD) announced today that the U.S. Food and Drug Administration (FDA) has registered the laboratory of Dipanjan Pan, MSc, PhD at the University of Maryland School of Medicine (UMSOM), as an approved laboratory development site for RNADD's Antisense COVID-19 molecular diagnostic test.

Read More